FrancophonIA/ELRC3.0 huggingface dataset:
English: Why has Actos been approved?
Estonian: Miks Actos heaks kiideti?
English: The company that markets Actos will produce educational material for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.
Estonian: Actost turustav ettevõte koostab ravimit määravatele arstidele teabematerjalid, milles selgitatakse südamepuudulikkuse ja kusepõie vähi võimalikku riski pioglitasooni sisaldavate ravimite kasutamisel, patsientide valikukriteeriume ning vajadust ravi regulaarselt läbi vaadata ja lõpetada, kui see ei ole patsientidele enam kasulik.
English: If Actos is used in combination with other diabetes medicines, other side effects may occur.
Estonian: Actose kasutamisel koos teiste diabeediravimitega võivad esineda ka muud kõrvalnähud.
English: The CHMP decided that Actos's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Actose kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Actos.
Estonian: See on ravimi Actos Euroopa avaliku hindamisaruande kokkuvõte.
English: What is Actos?
Estonian: Mis on Actos?
English: For more information about treatment with Actos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Actosega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Actos is a medicine that contains the active substance pioglitazone.
Estonian: Actos on ravim, mis sisaldab toimeainena pioglitasooni.
English: The active substance in Actos, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Estonian: Actose toimeaine pioglitasoon suurendab rakkude (rasva-, lihas- ja maksarakkude) tundlikkust insuliini suhtes, mis tähendab, et organism kasutab enda toodetavat insuliini paremini.
English: Other information about Actos:
Estonian: Muu teave Actose kohta
English: The recommended starting dose of Actos is 15 or 30 mg once a day.
Estonian: Actose soovitatav algannus on 15 või 30 mg üks kord ööpäevas.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Actos.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Actos is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Estonian: Actost kasutatakse eelkõige ülekaaluliste täiskasvanud (vähemalt 18-aastaste) patsientide II tüüpi diabeedi (suhkurtõve) raviks.
English: How does Actos work?
Estonian: Kuidas Actos toimib?
English: What is the risk associated with Actos?
Estonian: Mis riskid Actosega kaasnevad?
English: Some studies also looked at combining Actos with a sulphonylurea, insulin or metformin, or with the combination of metformin and a sulphonylurea.
Estonian: Mõnes uuringus vaadeldi ka Actose kasutamist koos sulfonüüluurearavimi, insuliini või metformiiniga või metformiini ja sulfonüüluurearavimi kombinatsiooniga.
English: Actos must not be used in patients who have problems with their liver, patients who have had heart failure (when the heart does not work as well as it should) or patients with diabetic ketoacidosis (a complication of diabetes).
Estonian: Actost ei tohi kasutada patsiendid, kellel on maksaprobleeme, südamepuudulikkus või diabeetiline ketoatsidoos (diabeedi teatud tüsistus).
English: Actos led to a decrease in the level of HbA1c, indicating that blood glucose levels had been reduced at doses of 15, 30 and 45 mg. Actos on its own was shown to be as effective as metformin and gliclazide.
Estonian: Actos vähendas HbA1c-sisaldust, mis tõendas, et annustega 15 mg, 30 mg ja 45 mg vere glükoosisisaldus vähenes.
English: For the full list of all side effects reported with Actos, see the package leaflet.
Estonian: Actose kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Actos also improved the glucose control obtained in type 2 diabetes when it was added to existing treatment with a sulphonylurea, insulin or metformin, or the combination of metformin and a sulphonylurea.
Estonian: Actos parandas II tüüpi diabeediga patsientide vere glükoosisisalduse reguleeritavust ka juhul, kui Actos lisati senisele ravile sulfonüüluurearavimi, insuliini või metformiiniga või metformiini ja sulfonüüluurearavimi kombinatsiooniga.
English: Actos has been compared with placebo (a dummy treatment), metformin and gliclazide (a sulphonylurea) in a number of studies.
Estonian: Actost võrreldi mitmes uuringus platseebo (näiv ravim), metformiini ja gliklasiidiga (teatud sulfonüüluurearavim).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Actos have also been included in the summary of product characteristics and the package leaflet.
Estonian: Actose omaduste kokkuvõttesse ja pakendi infolehele lisati ravimi ohutu ja tõhusa kasutamise teave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What benefit has Actos shown during the studies?
Estonian: Milles seisneb uuringute põhjal Actose kasulikkus?
English: The medicine can only be obtained with a prescription.
Estonian: Actos on retseptiravim.
English: How has Actos been studied?
Estonian: Kuidas Actost uuriti?
English: What is Actos used for?
Estonian: Milleks Actost kasutatakse?
English: How is Actos used?
Estonian: Kuidas Actost kasutatakse?
English: are continuously monitored.
Estonian: kasutamise kohta pidevat järelevalvet.
English: The recommended dose is one tablet once a day, preferably taken with food.
Estonian: Soovitatav annus on üks tablett ööpäevas, eelistatult koos toiduga.
English: does not cure HIV infection or AIDS, but it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: ei ravi HIV-infektsiooni ega AIDSi välja, kuid võib immuunsüsteemi kahjustumist ning AIDSiga kaasnevate infektsioonide ja haiguste teket edasi lükata.
English: Two medicines are bioequivalent when they produce the same levels of the active substances in the body and are therefore expected to have the same effect.
Estonian: Kaks ravimit on bioekvivalentsed, kui mõlemad tekitavad organismis sama toimeainesisalduse ja neil on seetõttu sama eeldatav toime.
English: It is a ‘generic medicine'.
Estonian: on geneeriline ravim.
English: In addition, it may be used in adolescents who are resistant to first-line treatments or who cannot take them because of side effects.
Estonian: Seda võib kasutada ka noorukite raviks, kes on esmavaliku ravimitele resistentsed või ei saa neid kõrvalnähtude tõttu kasutada.
English: is available as tablets (200 mg emtricitabine and 245 mg tenofovir disoproxil).
Estonian: turustatakse tablettidena (200 mg emtritsitabiini ja 245 mg tenofoviirdisoproksiili).
English: is an HIV medicine that is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: on HIV-ravim, mida kasutatakse koos vähemalt ühe muu HIV-ravimiga, et ravida omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese 1. tüüpi immuunpuudulikkuse viirusega (HIV-1) nakatunud täiskasvanuid.
English: outweighs the identified risk and it can be authorised for use in the EU.
Estonian: kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
English: on 28 April 2017.
Estonian: müügiloa, mis kehtib kogu Euroopa Liidus, 28. aprillil 2017.
English: used?
Estonian: kasutatakse?
English: This means that it contains the same active substances and works in the same way as a ‘reference medicine' already authorised in the EU called Truvada.
Estonian: sisaldab sama toimeainet ja toimib samamoodi nagu võrdlusravim Truvada, millel juba on Euroopa Liidus müügiluba.
English: and why it is authorised in the EU
Estonian: ja ELis müügiloa väljastamise põhjendus
English: has been shown to have comparable quality and to be bioequivalent to Truvada.
Estonian: võrreldav kvaliteet ja bioekvivalentsus ravimiga Truvada.
English: (emtricitabine / tenofovir disoproxil)
Estonian: (emtritsitabiin/tenofoviirdisoproksiil)
English: Studies on the benefits and risks of the active substances in the authorised use have already been carried out with the reference medicine, Truvada, and do not need to be repeated for Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Võrdlusravimiga Truvada on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Emtricitabine/Tenofovir disoproxil Krka d.d.
English: can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
Estonian: on retseptiravim ja ravi sellega peab alustama HIVinfektsiooni (nakkuse) ravis kogenud arst.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Emtricitabine/Tenofovir disoproxil Krka d.d.
English: contains two active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug' of tenofovir.
Estonian: sisaldab kaht toimeainet: nukleosiidset pöördtranskriptaasi inhibiitorit emtritsitabiini ja tenofoviiri eelravimit tenofoviirdisoproksiili.
English: Side effects reported with Emtricitabine/Tenofovir disoproxil Krka are carefully evaluated and any necessary action taken to protect patients.
Estonian: kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: For more informationabout using Emtricitabine/Tenofovir disoproxil Krka d.d., see the package leaflet or contact your doctor or pharmacist.
Estonian: kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/emtricitabinetenofovir-disoproxil-krka-dd. Information on the reference medicine can also be found on the Agency's website.
Estonian: Lisateave ravimi Emtricitabine/Tenofovir disoproxil Krka d.d kohta on ameti veebilehel: ema.europa.eu/en/medicines/human/EPAR/emtricitabinetenofovir-disoproxil-krka-dd.
English: As for every medicine, the company provided studies on the quality of Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Nagu iga ravimi korral, esitas ettevõte uuringud ravimi Emtricitabine/Tenofovir disoproxil Krka d.d.
English: work?
Estonian: uuriti?
English: What measures are being taken to ensure the safe and effective use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Mis meetmed võetakse, et tagada ravimi Emtricitabine/Tenofovir disoproxil Krka d.d.
English: Therefore, the Agency's view was that, as for Truvada, the benefit of Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Seetõttu on amet arvamusel, et nagu ka Truvada korral, ületab ravimi Emtricitabine/Tenofovir disoproxil Krka d.d.
English: Both emtricitabine and tenofovir work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected.
Estonian: Pöördtranskriptaas on HIVi tekitatav ensüüm, mis võimaldab viirusel organismi rakke nakatada ja neis paljuneda.
English: As for all medicines, data on the use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Nagu kõigi ravimite puhul, teostatakse ravimi Emtricitabine/Tenofovir disoproxil Krka d.d.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: will provide an information pack to doctors which covers the potential harmful effects of Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: turustaja varustab arstid teabepakmega, mis selgitab ravimi võimalikku kahjulikku toimet neerutalitlusele täiskasvanutel ja lastel.
English: The European Commission granted a marketing authorisation valid throughout the EU for Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Euroopa Komisjon andis ravimi Emtricitabine/Tenofovir disoproxil Krka d.d.
English: Emtricitabine/Tenofovir disoproxil Krka d.d., taken in combination with at least one other antiviral medicine, reduces the amount of HIV in the blood and keeps it at a low level.
Estonian: vähendab HIVi kogust veres ja hoiab selle sisalduse väikese.
English: Further information on Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Muu teave ravimi Emtricitabine/Tenofovir disoproxil Krka d.d.
English: What is Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Mis on Emtricitabine/Tenofovir disoproxil Krka d.d.
English: How does Emtricitabine/Tenofovir disoproxil Krka d.d.
Estonian: Kuidas Emtricitabine/Tenofovir disoproxil Krka d.d.
English: Packaging
Estonian: Manustamistee Pakend
English: The procedure started on 19 July 2007.
Estonian: Menetlus algas 19. juulil 2007.
English: A Decision was issued by the European Commission on 7 October 2008.
Estonian: Euroopa Komisjon tegi otsuse 7. oktoobril 2008.
English: The Marketing Authorisation Holder provided supplementary information on 23 November 2007 and 22 April 2008.
Estonian: Müügiloa hoidja esitas täiendava teabe 23. novembril 2007 ja 22. aprillil
English: Ref. EMEA/CHMP/384874/2008
Estonian: London, 7. oktoober 2008 Viide: EMEA/CHMP/554238/2008
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Ciprofloxacin Bayer and associated names International Non-Proprietary Name (INN): ciprofloxacin
Estonian: INIMRAVIMITE KOMITEE ARVAMUS PÄRAST ARTIKLI 30 KOHAST ESILDIST Ciprofloxacin Bayer ja sarnased nimetused Rahvusvaheline mittekaubanduslik nimetus (INN): tsiprofloksatsiin
English: Ciprofloxacin Bayer and associated names is an antibiotic, indicated for the treatment of uncomplicated and complicated infections, including severe infections, caused by ciprofloxacin susceptible pathogens.
Estonian: Ciprofloxacin Bayer ja sarnased nimetused on antibiootikum, mis on näidustatud tsiprofloksatsiini suhtes tundlike patogeenide põhjustatud tüsistusteta ja tüsistustega infektsioonide, sealhulgas raskete infektsioonide raviks.
English: During its July 2008 meeting, the CHMP, in the light of the overall submitted data and the scientific discussion within the Committee, was of the opinion that the proposal for the harmonisation of the SPC, Labelling and Package Leaflet was acceptable and that they should be amended.
Estonian: 2008. aasta juuli koosolekul oli inimravimite komitee, võttes arvesse kõiki esitatud andmeid ja komiteesisest teaduslikku arutelu, arvamusel, et ravimi omaduste kokkuvõtete, märgistuse ja pakendi infolehtede ühtlustamise ettepanek on vastuvõetav ning need dokumendid tuleb muuta.
English: This medicinal product belongs to the list of products identified in 2007 for SPC harmonisation.
Estonian: See ravim kuulub 2007. a ravimite loetellu, mille ravimi omaduste kokkuvõtted kuuluvad ühtlustamisele.
English: The basis for referral was that there were divergences in the Summaries of Product Characteristics (SPC) of Ciprofloxacin Bayer and associated names approved across EU Member States, with respect to the indications, the posology, the contra-indications and the special warnings and precautions for use.
Estonian: Esildise aluseks olid Ciprofloxacin Bayeri ja sarnaste nimetuste Euroopa Liidu liikmesriikides heakskiidetud ravimi omaduste kokkuvõtetes esinenud erinevused näidustustes, annustamises, vastunäidustustes ning hoiatustes ja ettevaatusabinõudes kasutamisel.
English: The CHMP gave a positive opinion on 24 July 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet for Ciprofloxacin Bayer and associated names.
Estonian: Inimravimite komitee esitas positiivse arvamuse 24. juulil 2008, soovitades ühtlustada Ciprofloxacin Bayeri ja sarnaste nimetuste ravimi omaduste kokkuvõtted, märgistused ja pakendi infolehed.
English: On 22 June 2007, France presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the nationally authorised Summaries of Product Characteristics (SPC), Labelling and Package Leaflet of the medicinal product Ciprofloxacin Bayer and associated names.
Estonian: 22. juunil 2007 esitas Prantsusmaa Euroopa Ravimiametile muudetud direktiivi 2001/83/EÜ artikli 30 alusel esildise Ciprofloxacin Bayeri ja sarnaste nimetuste liikmesriikides heakskiidetud ravimi omaduste kokkuvõtete, pakendi infolehtede ja märgistuste ühtlustamiseks.
English: It is available as immediate release film coated tablets, modified release film coated tablets, granules and solutions for oral suspension, solutions for infusion in bags, solutions for infusion in bottles and sachets.
Estonian: Ravimit turustatakse toimeainet kiiresti vabastavate õhukese polümeerkattega tablettidena, toimeainet modifitseeritult vabastavate õhukese polümeerkattega tablettidena, suukaudse suspensiooni valmistamiseks graanulite ja lahusena, kottides infusioonilahusena, pudelites infusioonilahusena ja kotikestes.
English: In the MRP Sweden is the Reference Member State and Austria, Belgium, Finland, France, Germany, Italy, Ireland, Luxembourg, Portugal, Spain and the United Kingdom are the Concerned Member States.
Estonian: Viiteliikmesriigiks on vastastikuse tunnustamise menetluses Rootsi ning puudutatud liikmesriikideks on Austria, Belgia, Soome, Prantsusmaa, Saksamaa, Itaalia, Iirimaa, Luksemburg, Portugal, Hispaania ning Ühendkuningriik.
English: 1, Avenue de la Gare L-1611
Estonian: 1, Avenue de la Gare L-1611 Luksemburg
English: Like all medicines, Viani can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka Viani põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: B-1332 Genval, Belgium
Estonian: B-1332 Genval, Belgia
English: In several EU Member States Viani Diskus and associated names (see Annex I) are approved through the Mutual Recognition Procedure (MRP).
Estonian: Mõnedes ELi liikmesriikides on Viani Diskus ja sarnased nimetused (vt I lisa) vastastikuse tunnustamise menetluse kaudu heaks kiidetud.
English: Allen Pharmazeutika Pharma GmbH, Albert-Schweitzer-Gasse 6 A-1140 Wien
Estonian: Allen Pharmazeutika Pharma GmbH, Albert-Schweitzer-Gasse 6, A-1140 Wien, Austria
English: - Viani may affect the normal production of steroid hormones in the body, particularly if you have taken high doses for long periods of time.
Estonian: - Viani võib mõjutada hormoonide normaalset tootmist organismis, eriti kui te olete kasutanud pikaajaliselt suuri annuseid.
English: Adults and adolescents 12 years and older:
Estonian: Täiskasvanud ja üle 12-aastased noorukid
English: OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF VIANI DISKUS AND ASSOCIATED NAMES (SEE ANNEX I)
Estonian: VIANI DISKUS'e JA SARNASTE NIMETUSTE (VT I LISA) TEADUSLIKU HINDAMISE ÜLDKOKKUVÕTE
English: GlaxoSmithKline AB Box 516, SE-169 29 Solna Sweden
Estonian: GlaxoSmithKline AB Box 516, SE-169 29 Solna Rootsi
English: • the CHMP considered the referral made under Article 6(13) of Commission Regulation (EC) N 1084/2003 for Viani Diskus and associated names (see Annex I)
Estonian: • inimtervishoius kasutatavate ravimite komitee kaalus komisjoni määruse (EÜ) nr 1084/2003 artikli 6 lõike 13 alusel tehtud esildist Viani Diskuse ja sarnaste nimetuste (vt I lisa) kohta;
English: What Viani is and what it is used for Before you take Viani How to take Viani Possible side effects How to store Viani Further information
Estonian: Mis ravim on Viani ja milleks seda kasutatakse Mida on vaja teada enne Viani kasutamist Kuidas Viani't kasutada Võimalikud kõrvaltoimed Kuidas Viani't säilitada Lisainfo
English: Viani Diskus is also used for the regular treatment of the symptoms of severe Chronic Obstructive Pulmonary Disease (COPD).
Estonian: Viani Diskus`t kasutatakse ka ägeda kroonilise obstruktiivse kopsuhaiguse (KOK) sümptomite regulaarseks raviks.
English: Do not use Viani to treat a sudden attack of breathlessness or wheezing as it will not help you immediately.
Estonian: Ärge kasutage Viani't järsku tekkiva hingamisraskuse või hingelduse leevendamiseks, kuna Viani ei aita teid otsekohe.
English: Viani should not be taken with medicines called β-blockers (such as atenolol, propranolol, sotalol), unless your doctor tells you to do so.
Estonian: Viani't ei tohi kasutada koos ravimitega, mida nimetatakse beeta-blokaatoriteks (nt atenolool, propranolool, sotalool), kui just arst ei määra nende ravimite kooskasutamist.
English: Do not use Viani after the expiry date which is stated on the label and carton.
Estonian: Ärge kasutage Viani't pärast kõlblikkusaega, mis on märgitud sildil ja karbil.
English: WHAT VIANI IS AND WHAT IT IS USED FOR
Estonian: MIS RAVIM ON VIANI JA MILLEKS SEDA KASUTATAKSE
English: Viani Diskus should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Estonian: VIANI kasutamine tuleb otsekohe lõpetada, hinnata patsiendi seisundit ning vajadusel rakendada alternatiivset ravi.
English: GlaxoSmithKline SA Parque Tecnologico de Madrid Calle Severo Ochoa 2, 28760 Tres Cantos, Madrid Spain
Estonian: GlaxoSmithKline SA Parque Tecnologico de Madrid, Calle Severo Ochoa 2, 28760, Tres Cantos, Madrid, Hispaania
English: Very rarely side effects may occur if you have taken high doses of Viani for a long time and you stop or reduce your dose suddenly.
Estonian: Väga harva võivad tekkida kõrvaltoimed, eriti kui olete võtnud Viani't pikemaajaliselt suures annuses ning kui te siis katkestate ravi või vähendate kiiresti annust.
English: Viani Diskus contains up to 12.5 milligrams of lactose in each dose.
Estonian: Viani Diskus sisaldab kuni 12,5 milligrammi laktoosi ühes annuses.
English: It is very important that you take your Viani every day as directed, until you are advised to stop by your doctor.
Estonian: On väga tähtis, et te manustaksite Viani't iga päev vastavalt juhistele, kuni arst soovitab ravimi kasutamise lõpetada.
English: If you take more Viani than you should
Estonian: Kui te kasutate Viani't rohkem kui ette nähtud
English: Viani Asthma clinical trials
Estonian: Astma kliinilised uuringud.
English: Viani contains salmeterol and fluticasone propionate which have differing modes of action.
Estonian: VIANI sisaldab salmeterooli ja flutikasoonpropionaati, millel on erinevad toimemehhanismid.
English: Do not stop taking Viani suddenly as this could make your symptoms worse and could cause problems with the body's hormones.
Estonian: Ärge lõpetage Viani manustamist järsku, kuna teie haigusnähud võivad halveneda ning tekkida võivad nihked organismi hormonaalsüsteemis.
English: There are no data available from clinical trials on overdose with Viani, however data on overdose with both drugs are given below:
Estonian: Puuduvad kliinilistest uuringutest saadud andmed VIANI üleannustamise kohta, kuid olemasolevad andmed mõlema komponendi üleannustamise kohta on toodud allpool.